Shining d' light on chronic kidney disease: Mechanisms that may underpin the cardiovascular benefit of vitamin D

Nephrology

Volumn 16, Issue 4, 2011, Pages 351-367

  Petchey, William G ^a   Johnson, David W ^a   Isbel, Nicole M ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

cardiovascular diseases; receptors; renal insufficiency; vitamin D

Indexed keywords

ALFACALCIDOL; CALCITRIOL; COLECALCIFEROL; DOXERCALCIFEROL; ERGOCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; PARICALCITOL; PLACEBO; VITAMIN D;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; ENDOTHELIAL DYSFUNCTION; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HEART VENTRICLE HYPERTROPHY; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROTEINURIA; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

ANIMALS; CALCIFEDIOL; CALCITRIOL; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; HUMANS; KIDNEY DISEASES; RISK ASSESSMENT; RISK FACTORS; VITAMIN D DEFICIENCY;

EID: 79955445900     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2011.01450.x     Document Type: Article

References (136)

1. Rakhit DJ, Marwick TH, Armstrong KA, Johnson DW, Leano R, Isbel NM,. Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease. Heart 2006; 92: 1402-8. (Pubitemid 44578827)
2. Kaisar MO, Isbel NM, Johnson DW,. Cardiovascular disease in patients with chronic kidney disease. A clinical review. Minerva. Urol. Nefrol. 2007; 59 (3): 281-97. (Pubitemid 350205658)
3. Kennedy R, Case C, Fathi R, Johnson D, Isbel N, Marwick TH,. Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? Am. J. Med. 2001; 110 (3): 198-204. (Pubitemid 32155515)
4. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al,. Hypovitaminosis D in medical inpatients. N. Engl. J. Med. 1998; 338: 777-83. (Pubitemid 28135983)
5. Ravani P, Malberti F, Tripepi G, et al,. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int. 2009; 75 (1): 88-95.
6. Holick MF,. Vitamin D deficiency. N. Engl. J. Med. 2007; 357 (3): 266-81.
7. Dobnig H, Pilz S, Scharnagl H, et al,. Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch. Intern. Med. 2008; 168 (12): 1340-9. (Pubitemid 351930842)
8. Wolf M, Shah A, Gutierrez O, et al,. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007; 72: 1004-13. (Pubitemid 47530570)
9. Wang AY, Lam CW, Sanderson JE, et al,. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am. J. Clin. Nutr. 2008; 87: 1631-8. (Pubitemid 351872624)
10. Inaguma D, Nagaya H, Hara K, et al,. Relationship between serum 1,25-dihydroxyvitamin D and mortality in patients with pre-dialysis chronic kidney disease. Clin. Exp. Nephrol. 2008; 12 (2): 126-31.
11. Mehrotra R, Kermah DA, Salusky IB, et al,. Chronic kidney disease, hypovitaminosis D, and mortality in the United States. Kidney Int. 2009; 76 (9): 977-83.
12. Giovannucci E, Liu Y, Hollis BW, Rimm EB,. 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch. Intern. Med. 2008; 168 (11): 1174-80. (Pubitemid 351831400)
13. Melamed ML, Michos ED, Post W, Astor B,. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch. Intern. Med. 2008; 168 (15): 1629-37.
14. Pilz S, Dobnig H, Fischer JE, et al,. Low vitamin D levels predict stroke in patients referred to coronary angiography. Stroke 2008; 39 (9): 2611-3.
15. Wang TJ, Pencina MJ, Booth SL, et al,. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503-11.
16. Semba RD, Houston DK, Bandinelli S, et al,. Relationship of 25-hydroxyvitamin D with all-cause and cardiovascular disease mortality in older community-dwelling adults. Eur. J. Clin. Nutr. 2010; 64 (2): 203-9.
17. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P,. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J. Am. Soc. Nephrol. 2009; 20 (12): 2631-9.
18. Shoben AB, Rudser KD, de Boer IH, Young B, Kestenbaum B,. Association of oral calcitriol with improved survival in nondialyzed CKD. J. Am. Soc. Nephrol. 2008; 19 (8): 1613-9.
19. Marco MP, Craver L, Betriu A, Belart M, Fibla J, Fernandez E,. Higher impact of mineral metabolism on cardiovascular mortality in a European hemodialysis population. Kidney Int. Suppl. 2003; 85: S111-14. (Pubitemid 36608935)
20. Teng M, Wolf M, Lowrie EG, Ofsthun MN, Lazarus JM, Thadhani R,. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N. Engl. J. Med. 2003; 349: 446-56. (Pubitemid 36910023)
21. Shoji T, Shinohara K, Kimoto E, et al,. Lower risk for cardiovascular mortality in oral 1α-hydroxy vitamin D3 users in a haemodialysis population. Nephrol. Dial. Transplant. 2004; 19: 179-84. (Pubitemid 38072630)
22. Teng M, Wolf M, Ofsthun MN, et al,. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J. Am. Soc. Nephrol. 2005; 16: 1115-25. (Pubitemid 41710323)
23. Melamed ML, Eustace JA, Plantinga L, et al,. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int. 2006; 70 (2): 351-7. (Pubitemid 44086585)
24. Tentori F, Hunt WC, Stidley CA, et al,. Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int. 2006; 70: 1858-65. (Pubitemid 44684819)
25. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al,. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int. 2008; 74 (8): 1070-8.
26. Bostick RM, Kushi LH, Wu Y, Meyer KA, Sellers TA, Folsom AR,. Relation of calcium, vitamin D, and dairy food intake to ischemic heart disease mortality among postmenopausal women. Am. J. Epidemiol. 1999; 149 (2): 151-61. (Pubitemid 29039518)
27. Trivedi DP, Doll R, Khaw KT,. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double blind controlled trial. BMJ. 2003; 326 (7387): 469.
28. Schleithoff SS, Zitterman A, Tenderich G, Berthold HK, Stehle P, Koerfer R,. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am. J. Clin. Nutr. 2006; 83: 754-9. (Pubitemid 44713136)
29. Hsia J, Heiss G, Ren H, et al,. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115 (7): 846-54. (Pubitemid 46294725)
30. Autier P, Gandini S,. Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch. Intern. Med. 2007; 167 (16): 1730-7. (Pubitemid 47403059)
31. Jones G,. Expanding role for vitamin D in chronic kidney disease: importance of blood 25-OH-D levels and extra-renal 1alpha-hydroxylase in the classical and nonclassical actions of 1alpha,25-dihydroxyvitamin D(3). Semin. Dial. 2007; 20 (4): 316-24.
32. Martinez I, Saracho R, Montenegro J, Llach F,. A deficit of calcitriol synthesis may not be the initial factor in the pathogenesis of secondary hyperparathyroidism. Nephrol. Dial. Transplant. 1996; 11 (Suppl 3): 22-8. (Pubitemid 26278582)
33. Chonchol M, Scragg R,. 25-Hydroxyvitamin D, insulin resistance, and kidney function in the Third National Health and Nutrition Examination Survey. Kidney Int. 2007; 71 (2): 134-9. (Pubitemid 46094686)
34. Targher G, Bertolini L, Padovani R, et al,. Serum 25-hydroxyvitamin D3 concentrations and carotid artery intima-media thickness among type 2 diabetic patients. Clin. Endocrinol. (Oxf) 2006; 65: 593-7. (Pubitemid 44583818)
35. von Hurst PR, Stonehouse W, Coad J,. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br. J. Nutr. 2010; 103 (4): 549-55.
36. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D,. Calcium-independent and 1,25(OH)2D3-dependant regulation of the renin-angiotensin system in 1α-hydroxylase knockout mice. Kidney Int. 2008; 74: 170-9. (Pubitemid 351915078)
37. Rammos G, Tseke P, Ziakka S,. Vitamin D, the renin-angiotensin system, and insulin resistance. Int. Urol. Nephrol. 2008; 40: 419-26.
38. Maruotti N, Corrado A, Grano M, Colucci S, Cantatore FP,. Normal and osteoporotic human osteoblast behaviour after 1,25-dihydroxy-vitamin D(3) stimulation. Rheumatol. Int. 2009; 29 (6): 667-72.
39. Kanazawa I, Yamaguchi T, Yamamoto M, et al,. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 2009; 94 (1): 45-9.
40. Lee NK, Sowa H, Hinoi E, et al,. Endocrine regulation of energy metabolism by the skeleton. Cell 2007; 130 (3): 456-69. (Pubitemid 47208519)
41. Atkins GJ, Anderson PH, Findlay DM, et al,. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 2007; 40 (6): 1517-28. (Pubitemid 46756427)
42. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D,. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes. Metab. 2008; 10: 185-97. (Pubitemid 351249776)
43. Norman AW, Frankel JB, Heldt AM, Grodsky GM,. Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 1980; 209 (4458): 823-5. (Pubitemid 10017495)
44. Sergeev IN, Rhoten WB,. 1,25-Dihydroxyvitamin D3 evokes oscillations of intracellular calcium in a pancreatic β-cell line. Endocrinology 1995; 136: 2852-61.
45. Quesada JM, Martín-Malo A, Santiago J, et al,. Effect of calcitriol on insulin secretion in uraemia. Nephrol. Dial. Transplant. 1990; 5: 1013-7.
46. Mak RH,. Amelioration of hypertension and insulin resistance by 1,25-dihydroxycholecalciferol in hemodialysis patients. Pediatr. Nephrol. 1992; 6 (4): 345-8.
47. Mak RH,. Intravenous 1,25 dihydroxycholecalciferol corrects glucose intolerance in hemodialysis patients. Kidney Int. 1992; 41 (4): 1049-54.
48. Türk S, Yeksan M, Tamer N, Gürbilek M, Erdogan Y, Erkul A. Effect of 1,25 (OH)2 D3 treatment on glucose intolerance in uraemia. Nephrol. Dial. Transplant. 1992; 7: 1207-12. (Pubitemid 23014448)
49. Allegra V, Luisetto G, Mengozzi G, Martimbianco L, Vasile A,. Glucose-induced insulin secretion in uremia: role of 1 alpha,25(HO)2-vitamin D3. Nephron 1994; 68 (1): 41-7. (Pubitemid 24251186)
50. Lin SH, Lin YF, Lu KC, et al,. Effects of intravenous calcitriol on lipid profiles and glucose tolerance in uraemic patients with secondary hyperparathyroidism. Clin. Sci. (Lond) 1994; 87 (5): 533-8.
51. Kautzky-Willer A, Pacini G, Barnas U, et al,. Intravenous calcitriol normalizes insulin sensitivity in uremic patients. Kidney Int. 1995; 47 (1): 200-6.
52. Lamb EJ, Fluck RJ, Venton TR, Woodhead JS, Raine AE, Dawnay AB,. Effects of parathyroid hormone and 1,25(OH2)D3 on protein glycation in moderate uraemia. Nephron 1996; 74 (2): 295-300. (Pubitemid 26326698)
53. Gunal AI, Celiker H, Celebi H, Ustundag B, Gunal SY,. Intravenous alfacalcidol improves insulin resistance in hemodialysis patients. Clin. Nephrol. 1997; 48 (2): 109-13. (Pubitemid 27371040)
54. Mak RH,. 1,25-Dihydroxyvitamin D3 corrects insulin and lipid abnormalities in uremia. Kidney Int. 1998; 53 (5): 1353-7. (Pubitemid 28316898)
55. Khajehdehi P, Taheri S,. Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate. J. Ren. Nutr. 2003; 13 (2): 78-83. (Pubitemid 38368762)
56. Strõzecki P, Kretowicz M, Odrow-Sypniewska G, Manitius J,. The influence of intravenous 1,25(OH)2D3 therapy on glucose metabolism in hemodialyzed patients with secondary hyperparathyroidism. Ren. Fail. 2004; 26 (4): 345-8. (Pubitemid 39167608)
57. Blair D, Byham-Gray L, Lewis E, McCaffrey S,. Prevalence of vitamin D [25(OH)D] deficiency and effects of supplementation with ergocalciferol (vitamin D2) in stage 5 chronic kidney disease patients. J. Ren. Nutr. 2008; 18 (4): 375-82. (Pubitemid 351818240)
58. Hak AE, Stehouwer CD, Bots ML, et al,. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women. Arterioscler. Thromb. Vasc. Biol. 1999; 19 (8): 1986-91. (Pubitemid 29379933)
59. Festa A, D'Agostino R, Jr, Williams K, et al,. The relation of body fat mass and distribution to markers of chronic inflammation. Int. J. Obes. Relat. Metab. Disord. 2001; 25 (10): 1407-15. (Pubitemid 32977855)
60. Lee YH, Pratley RE,. The evolving role of inflammation in obesity and the metabolic syndrome. Curr. Diab. Rep. 2005; 5 (1): 70-5. (Pubitemid 40277804)
61. Wu-Wong JR,. Endothelial dysfunction and chronic kidney disease: treatment options. Curr. Opin. Investig. Drugs 2008; 9 (9): 970-82.
62. Ross R,. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362 (6423): 801-9. (Pubitemid 23132154)
63. Giachelli CM,. Vascular calcification mechanisms. J. Am. Soc. Nephrol. 2004; 15 (12): 2959-64. (Pubitemid 39578826)
64. Wang P, Anderson PO, Chen S, Paulsson KM, Sjögren HO, Li S,. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int. Immunopharmacol. 2001; 1 (4): 803-12. (Pubitemid 32206542)
65. van Etten E, Mathieu C,. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J. Steroid. Biochem. Mol. Biol. 2005; 97: 93-101.
66. Andress D,. Nonclassical aspects of differential vitamin D receptor activation: implications for survival in patients with chronic kidney disease. Drugs 2007; 67 (14): 1999-2012. (Pubitemid 47524562)
67. Tan X, Wen X, Liu Y,. Paricalcitriol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-ÎB signaling. J. Am. Soc. Nephrol. 2008; 19: 1741-52.
68. Riancho JA, Zarrabeitia MT, de Francisco ALM, et al,. Vitamin D therapy modulates cytokine secretion in patients with renal failure. Nephron 1993; 65: 364-8. (Pubitemid 23321232)
69. Tsukamoto Y, Nagaba Y, Izumida I, Morishita T, Saitoh M,. Comparison of effects of calcitriol and calcium carbonate on secretion of interleukin-1β and tumour necrosis factor-α by uraemic peripheral blood mononuclear cells. Nephrol. Dial. Transplant. 1996; 11 (Suppl 3): 15-21. (Pubitemid 26278581)
70. Panichi V, De Pietro S, Andreini B, et al,. Calcitriol modulates in vivo and in vitro cytokine production: a role for intracellular calcium. Kidney Int. 1998; 54: 1463-9. (Pubitemid 28502888)
71. Jaroszynski AJ, Ksiazek A,. Changing relationships between serum IL-1, IL-6, and TNF-alpha and dynamic tests of parathyroid gland function in haemodialysis patients with severe hyperparathyroidism in response to calcitriol therapy. Nephrol. Dial. Transplant. 2000; 15 (10): 1718-9.
72. Moe SM, Zekonis M, Harezlak J, et al,. A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol. Am. J. Kidney Dis. 2001; 38 (4): 792-802.
73. Türk S, Akbulut M, Yildiz A, et al,. Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density. Nephron 2002; 90: 188-94. (Pubitemid 34701995)
74. Borazan A, Ustun H, Cefle A, Sekitmez N, Yilmaz A,. Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels. J. Int. Med. Res. 2003; 31 (6): 489-96. (Pubitemid 38008683)
75. Yonemura K, Sugiura T, Yamashita F, Matsushima H, Hishida A,. Supplementation with alfacalcidol increases protein intake and serum albumin concentration in patients undergoing hemodialysis with hypoalbuminemia: possible role of tumor necrosis factor-α. Blood Purif. 2004; 22: 210-5. (Pubitemid 38420858)
76. Alborzi P, Patel NA, Peterson C, et al,. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008; 52 (2): 249-55.
77. Matias PJ, Jorge C, Ferreira C, et al,. Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin. J. Am. Soc. Nephrol. 2010; 5 (5): 905-11.
78. Kristal-Boneh E, Froom P, Harari G, Ribak J,. Association of calcitriol and blood pressure in normotensive men. Hypertension 1997; 30 (5): 1289-94. (Pubitemid 27476193)
79. Lind L, Hanni A, Lithell H, Hvarfner A, Sorensen OH, Ljunghall S,. Vitamin D is related to blood pressure and other cardiovascular risk factors in middle-aged men. Am. J. Hypertens. 1995; 8 (9): 894-901.
80. Burgess ED, Hawkins RG, Watanabe M,. Interaction of 1,25-dihydroxyvitamin D and plasma renin activity in high renin essential hypertension. Am. J. Hypertens. 1990; 3 (12 Pt 1): 903-5.
81. Tomaschitz A, Pilz S, Ritz E, et al,. Independent association between 1,25-dihydroxyvitamin D, 25-hydroxyvitamin D and the renin-angiotensin system: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin. Chim. Acta. 2010; 411 (17-18): 1354-60.
82. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP,. 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J. Clin. Invest. 2002; 110 (2): 229-38. (Pubitemid 34787360)
83. Simpson RU, Hershey SHH, Nibbelink KA,. Characterization of heart size and blood pressure in the vitamin D receptor knockout mice. J. Steroid. Biochem. Mol. Biol. 2007; 103 (3-5): 521-4. (Pubitemid 46420533)
84. Bodyak N, Ayus JC, Achinger S, et al,. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc. Natl. Acad. Sci. U. S. A. 2007; 104 (43): 16810-5. (Pubitemid 350210947)
85. Freundlich M, Quiroz Y, Zhang Z, et al,. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int. 2008; 74 (11): 1394-402.
86. Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD,. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest. 2002; 109 (11): 1417-27. (Pubitemid 34596167)
87. Nguyen G, Contrepas A,. Physiology and pharmacology of the (pro)renin receptor. Curr. Opin. Pharmacol. 2008; 8 (2): 127-32.
88. Tan X, He W, Liu Y,. Combination therapy with paricalcitol and trandolapril reduces renal fibrosis in obstructive nephropathy. Kidney Int. 2009; 76 (12): 1248-57.
89. Park CW, Oh YS, Shin YS, et al,. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis with secondary hyperparathyroidism. Am. J. Kidney Dis. 1999; 33 (1): 73-81.
90. Kong J, Kim GH, Wei M, et al,. Therapeutic effects of vitamin D analogs on cardiac hypertrophy in spontaneously hypertensive rats. Am. J. Pathol. 2010; 177 (2): 622-31.
91. McGonigle RJ, Timmis AD, Keenan J, Jewitt DE, Weston MJ, Parsons V,. The influence of 1 alpha-hydroxycholecalciferol on left ventricular function in end-stage renal failure. Proc. Eur. Dial. Transplant. Assoc. 1981; 18: 579-85.
92. McGonigle RJ, Fowler MB, Timmis AB, Weston MJ, Parsons V,. Uremic cardiomyopathy: potential role of vitamin D and parathyroid hormone. Nephron 1984; 36 (2): 94-100. (Pubitemid 14212640)
93. Lemmila S, Saha H, Virtanen V, Ala-Houhala I, Pasternack A,. Effect of intravenous calcitriol on cardiac systolic and diastolic function in patients on hemodialysis. Am. J. Nephrol. 1998; 18 (5): 404-10. (Pubitemid 28442103)
94. Kim HW, Park CW, Shin YS, et al,. Calcitriol regresses cardiac hypertrophy and QT dispersion in secondary hyperparathyroidism on hemodialysis. Nephron Clin. Pract. 2006; 102: c21-9.
95. Singh NP, Sahni V, Garg D, Nair M,. Effect of pharmacological suppression of secondary hyperparathyroidism on cardiovascular hemodynamics in predialysis CKD patients: a preliminary observation. Hemodial. Int. 2007; 11: 417-23. (Pubitemid 47534866)
96. Keane WF, Eknoyan G,. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am. J. Kidney Dis. 1999; 33 (5): 1004-10. (Pubitemid 29214705)
97. de Boer IH, Ioannou GN, Kestenbaum B, Brunzell JD, Weiss NS,. 25-Hydroxyvitamin D levels and albuminuria in the Third National Health and Nutrition Examination Survey (NHANES III). Am. J. Kidney Dis. 2007; 50 (1): 69-77. (Pubitemid 46962855)
98. Cuppari L, Carvalho AB, Draibe SA,. Vitamin D status of chronic kidney disease patients living in a sunny country. J. Ren. Nutr. 2008; 18 (5): 408-14.
99. Wang Y, Zhou C, Minto AW, et al,. Altered vitamin D metabolism in type II diabetic mouse glomeruli may provide protection from diabetic nephropathy. Kidney Int. 2006; 70: 882-91. (Pubitemid 44285965)
100. Piecha G, Kokeny G, Nakagawa K, et al,. Calcimimetic R-568 or calcitriol: equally beneficial on progression of renal damage in subtotally nephrectomized rats. Am. J. Physiol. Renal. Physiol. 2008; 294: F748-57.
101. Xiao H, Shi W, Liu S, et al,. 1,25-Dihydroxyvitamin D3 prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/Akt-signaling pathway. Am. J. Nephrol. 2009; 30 (1): 34-43.
102. Tryggvason K, Patrakka J, Wartiovaara J,. Hereditary proteinuria syndromes and mechanisms of proteinuria. N. Engl. J. Med. 2006; 354: 1387-401.
103. Yamauchi K, Takano Y, Kasai A, et al,. Screening and identification of substances that regulate nephrin gene expression using engineered reporter podocytes. Kidney Int. 2006; 70: 892-900. (Pubitemid 44285966)
104. Panichi V, Migliori M, Taccola D, et al,. Effects of 1,25 (OH)2D3 in experimental mesangial proliferative nephritis in rats. Kidney Int. 2001; 60: 87-95. (Pubitemid 32587543)
105. Makibayashi K, Tatematsu M, Hirata M, et al,. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am. J. Pathol. 2001; 158 (5): 1733-41. (Pubitemid 32422938)
106. Kwoh C, Shannon MB, Miner JH, Shaw A,. Pathogenesis of nonimmune glomerulopathies. Annu. Rev. Pathol. 2006; 1: 349-74.
107. Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E,. Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int. 1998; 53: 1696-705. (Pubitemid 28243754)
108. de Zeeuw D, Agarwal R, Amdahl M, et al,. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376 (9752): 1543-51.
109. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N,. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am. J. Kidney Dis. 2009; 54 (4): 647-52.
110. Agarwal R, Acharya M, Tian J, et al,. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int. 2005; 68 (6): 2823-8. (Pubitemid 43251029)
111. Szeto C, Chow K, Kwan BC, Chung K, Leung C, Li PK,. Oral calcitriol for the treatment of persistence proteinuria in immunoglobulin a nephropathy: an uncontrolled trial. Am. J. Kidney Dis. 2008; 51 (5): 724-31. (Pubitemid 351626254)
112. Sniderman AD, Solhpour A, Alam A, Williams K, Sloand JA,. Cardiovascular death in dialysis patients: lessons we can learn from AURORA. Clin. J. Am. Soc. Nephrol. 2010; 5 (2): 335-40.
113. Koleganova N, Piecha G, Ritz E, Gross ML,. Calcitriol ameliorates capillary deficit and fibrosis of the heart in subtotally nephrectomized rats. Nephrol. Dial. Transplant. 2009; 24 (3): 778-87.
114. Basalyga DM, Simionescu DT, Xiong W, Baxter BT, Starcher BC, Vyavahare NR,. Elastin degradation and calcification in an abdominal aorta injury model: role of matrix metalloproteinases. Circulation 2004; 110 (22): 3480-7. (Pubitemid 39602227)
115. Rahman A, Hershey SHH, Ahmed S, Nibbelink KA, Simpson RU,. Heart extracellular matrix gene expression profile in the vitamin D receptor knockout mice. J. Steroid. Biochem. Mol. Biol. 2007; 103: 416-9. (Pubitemid 46415673)
116. Talmor Y, Golan E, Benchetrit S, et al,. Calcitriol blunts the deleterious impact of advanced glycation end products on endothelial cells. Am. J. Physiol. Renal. Physiol. 2008; 294 (5): F1059-64.
117. Wu-Wong JR, Nakane M, Ma J,. Vitamin D analogs modulate the expression of plasminogen activator inhibitor-1, thrombospondin-1 and thrombomodulin in human aortic smooth muscle cells. J. Vasc. Res. 2007; 44: 11-8. (Pubitemid 46105689)
118. Wu-Wong JR,. The potential for vitamin D receptor activation in cardiovascular research. Expert. Opin. Investig. Drugs 2007; 16 (4): 407-11. (Pubitemid 46554459)
119. Margolis JR, Chen JT, Kong Y, Peter RH, Behar VS, Kisslo JA,. The diagnostic and prognostic significance of coronary artery calcification. A report of 800 cases. Radiology 1980; 137 (3): 609-16. (Pubitemid 11203687)
120. London GM, Guerin AP, Verbeke FH, et al,. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J. Am. Soc. Nephrol. 2007; 18 (2): 613-20. (Pubitemid 46193327)
121. Raggi P, Bellasi A, Ferramosca E, Block GA, Muntner P,. Pulse wave velocity is inversely related to vertebral bone density in hemodialysis patients. Hypertension 2007; 49: 1278-84. (Pubitemid 46809369)
122. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G,. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997; 89 (5): 747-54. (Pubitemid 27516177)
123. Bellows CG, Reimers SM, Heersche JN,. Expression of mRNAs for type-I collagen, bone sialoprotein, osteocalcin, and osteopontin at different stages of osteoblastic differentiation and their regulation by 1,25 dihydroxyvitamin D3. Cell Tissue Res. 1999; 297 (2): 249-59. (Pubitemid 29366470)
124. Drissi H, Pouliot A, Koolloos C, et al,. 1,25-(OH)2-vitamin D3 suppresses the bone-related Runx2/Cbfa1 gene promoter. Exp. Cell Res. 2002; 274 (2): 323-33.
125. Fraser JD, Price PA,. Induction of matrix Gla protein synthesis during prolonged 1,25-dihydroxyvitamin D3 treatment of osteosarcoma cells. Calcif. Tissue. Int. 1990; 46 (4): 270-9. (Pubitemid 20142836)
126. Niederhoffer N, Lartaud-Idjouadiene I, Giummelly P, Duvivier C, Peslin R, Atkinson J,. Calcification of medial elastic fibers and aortic elasticity. Hypertension 1997; 29 (4): 999-1006. (Pubitemid 27152472)
127. Haffner D, Hocher B, Muller D, et al,. Systemic cardiovascular disease in uremic rats induced by 1,25(OH)2D3. J. Hypertens. 2005; 23 (5): 1067-75. (Pubitemid 40637927)
128. Brancaccio D, Cozzolino M, Galassi A, et al,. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs. J. Nephrol. 2007; 20 (1): 3-9.
129. Sprague SM, Moe SM,. Safety and efficacy of long-term treatment of secondary hyperparathyroidism by low-dose intravenous calcitriol. Am. J. Kidney Dis. 1992; 19: 532-9.
130. Tamagaki K, Yuan Q, Ohkawa H, et al,. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine induced uraemia. Nephrol. Dial. Transplant. 2006; 21 (3): 651-9. (Pubitemid 43372910)
131. Zitterman A, Schleithoff SS, Koerfer R,. Vitamin D and vascular calcification. Curr. Opin. Lipidol. 2007; 18: 41-6. (Pubitemid 46090236)
132. Somjen D, Weisman Y, Kohen F, et al,. 25-hydroxyvitamin D3-1alpha-hydroxylase is expressed in human vascular smooth muscle cells and is upregulated by parathyroid hormone and estrogenic compounds. Circulation 2005; 111 (13): 1666-71. (Pubitemid 40525167)
133. Larsson TE,. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol. Dial. Transplant. 2010; 25 (5): 1376-81.
134. Juppner H, Wolf M, Salusky IB,. FGF-23: More than a regulator of renal phosphate handling? J. Bone Miner. Res. 2010; 25 (10): 2091-7.
135. Baker LRI, Muir JW, Sharman VL, et al,. Controlled trial of calcitriol in hemodialysis patients. Clin. Nephrol. 1986; 26 (4): 185-91. (Pubitemid 16025308)
136. Morosetti M, Jankovic L, Palombo G, et al,. High-dose calcitriol therapy and progression of cardiac vascular calcifications. J. Nephrol. 2008; 21 (4): 603-8.